Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Santoni M, et al. Among authors: caffo o. Cancers (Basel). 2019 Dec 30;12(1):84. doi: 10.3390/cancers12010084. Cancers (Basel). 2019. PMID: 31905816 Free PMC article.
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. Caffo O, et al. BJU Int. 2015 May;115(5):764-71. doi: 10.1111/bju.12857. Epub 2014 Oct 8. BJU Int. 2015. PMID: 24988879
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. Caffo O, et al. Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25. Eur Urol. 2015. PMID: 25457020
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, Macrini S, Spizzo G, Aieta M, Messina C, Tucci M, Lodde M, Mansueto G, Zucali PA, Alesini D, D'Angelo A, Massari F, Morelli F, Procopio G, Ratta R, Fratino L, Lo Re G, Pegoraro MC, Zustovich F, Vicario G, Ruatta F, Federico P, La Russa F, Burgio SL, Maines F, Veccia A, Galligioni E. Caffo O, et al. Urol Oncol. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016. Epub 2015 Apr 20. Urol Oncol. 2015. PMID: 25907622
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Maines F, Caffo O, De Giorgi U, Fratino L, Lo Re G, Zagonel V, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Basso U, Fraccon AP, Vicario G, Conteduca V, Galligioni E. Maines F, et al. Among authors: caffo o. Clin Genitourin Cancer. 2016 Feb;14(1):48-55. doi: 10.1016/j.clgc.2015.07.019. Epub 2015 Aug 6. Clin Genitourin Cancer. 2016. PMID: 26382222
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Zagonel V, Veccia A, Lolli C, Maines F, De Giorgi U. Conteduca V, et al. Among authors: caffo o. Future Oncol. 2015;11(21):2881-91. doi: 10.2217/fon.15.158. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26436290
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. Veccia A, et al. Among authors: caffo o. Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18. Future Oncol. 2016. PMID: 26776493
237 results